EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced findings which demonstrated that annualized relapse rates remained low and Expanded Disability Status Scale scores were stable in people with relapsing multiple sclerosis treated with investigational evobrutinib through more than three and half years.
October 26, 2022
· 8 min read